TopiVert, a London, UK-based start-up that focuses on developing topical medicines for inflammatory diseases of the eye and gut, has raised £8m in funding.
Backers include Imperial Innovations Group (AIM: IVO) and SV Life Sciences.
TopiVert has licensed NSKI (narrow spectrum kinase inhibitor) related intellectual property from RespiVert Ltd., for exclusive use in discovering and developing NSKIs for inflammatory diseases of the eye and gut. The two companies will also enter into an exclusive drug discovery collaboration aimed at identifying new NSKIs.
TopiVert will receive exclusive rights to select and develop resulting NSKIs for the treatment of inflammatory diseases of the eye and gut, such as uveitis and inflammatory bowel disease, while RespiVert will receive exclusive rights to select and develop resulting NSKIs for the treatment of other indications, such as inflammatory diseases of the lungs.
Led by Chairman Allan Baxter, and Chief Scientific Officer Steve Webber. TopiVert will operate from the Imperial College Incubator, where RespiVert, previously backed by Imperial Innovations and SV Life Sciences, remains a tenant.
In connection with the investment, Maina Bhaman, Director of Healthcare Investments at Imperial Innovations, had joined the company’s board as Non-Executive Director.